Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

abstract：:We compared the antidepressant efficacy and patient tolerance of two different doses of milnacipran (75 mg and 150 mg daily) in 66 outpatients with major depression, using the 17-item Hamilton Depression Rating Scale (HDRS). Only new patients who had never experienced frank depressive episodes before, or those who had...

journal_title：International clinical psychopharmacology

authors： Kanemoto K,Matsubara M,Yamashita K,Tarao Y,Inada E,Sekine T

更新日期：2004-11-01 00:00:00

abstract：:The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

journal_title：International clinical psychopharmacology

authors： Whitworth AB,Fleischhacker WW

更新日期：1995-01-01 00:00:00

abstract：:Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

journal_title：International clinical psychopharmacology

authors： Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

更新日期：2014-03-01 00:00:00

abstract：:In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

journal_title：International clinical psychopharmacology

authors： Lecrubier Y,Weiller E

更新日期：1997-10-01 00:00:00

abstract：:This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

更新日期：2018-07-01 00:00:00

abstract：:We report the case of a patient with schizophrenia who developed urinary hesitancy and eventually urinary retention, 6 months after continuous treatment with ziprasidone; he had been administered no other medication during this time. The micturition difficulties resolved immediately upon discontinuation of ziprasidone...

journal_title：International clinical psychopharmacology

authors： Xomalis D,Bozikas VP,Garyfallos G,Nikolaidis N,Giouzepas J,Fokas K

更新日期：2006-01-01 00:00:00

abstract：:Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

journal_title：International clinical psychopharmacology

authors： Eriksson E

更新日期：1999-05-01 00:00:00

abstract：:Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...

journal_title：International clinical psychopharmacology

authors： Slaap BR,Boshuisen ML,van Roon AM,den Boer JA

更新日期：2002-03-01 00:00:00

abstract：:The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

journal_title：International clinical psychopharmacology

authors： Barak Y,Swartz M,Plopsky I

更新日期：2005-11-01 00:00:00

abstract：:In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...

journal_title：International clinical psychopharmacology

authors： Greil W,Kleindienst N

更新日期：1999-09-01 00:00:00

abstract：:Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

journal_title：International clinical psychopharmacology

authors： Emsley RA,Raniwalla J,Bailey PJ,Jones AM

更新日期：2000-05-01 00:00:00

abstract：:Since the discovery that clomipramine was effective in the treatment of obsessive-compulsive disorder (OCD), trials of several different medications for OCD have been published. The question of which agent, if any, is the medication of choice in OCD is of real clinical concern. Published clinical trials were collected...

journal_title：International clinical psychopharmacology

authors： Stein DJ,Spadaccini E,Hollander E

更新日期：1995-03-01 00:00:00

abstract：:Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...

journal_title：International clinical psychopharmacology

authors： Hägg S,Lindblom Y,Mjörndal T,Adolfsson R

更新日期：2006-03-01 00:00:00

abstract：:Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...

journal_title：International clinical psychopharmacology

authors： Möller HJ

更新日期：1998-03-01 00:00:00

abstract：:We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

journal_title：International clinical psychopharmacology

authors： Velayudhan L,Kirchner V

更新日期：2005-03-01 00:00:00

abstract：:Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...

journal_title：International clinical psychopharmacology

authors： Kessing LV,Forman JL,Andersen PK

更新日期：2011-11-01 00:00:00

abstract：:Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

journal_title：International clinical psychopharmacology

authors： Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

更新日期：2019-03-01 00:00:00

abstract：:In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. There were 83, 96 and 90 patients evaluated in the respective treatment groups; treatment lasted 6 weeks. Patients w...

journal_title：International clinical psychopharmacology

authors： Doogan DP,Langdon CJ

更新日期：1994-07-01 00:00:00

abstract：:Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

journal_title：International clinical psychopharmacology

authors： Mattila M,Seppala T,Mattila MJ

更新日期：1988-07-01 00:00:00

abstract：:Most depressive disorders can be viewed as recurrent conditions that may reduce quality of life and productivity. Results of controlled clinical trials indicate that patients should receive 4-6 months of continuation therapy after remission of the acute phase of the illness. Patients at risk of recurrent episodes, how...

journal_title：International clinical psychopharmacology

authors： Kasper S

更新日期：1993-01-01 00:00:00

abstract：:The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

journal_title：International clinical psychopharmacology

authors： Peuskens J,Van Baelen B,De Smedt C,Lemmens P

更新日期：2000-11-01 00:00:00

abstract：:The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

journal_title：International clinical psychopharmacology

authors： Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

更新日期：1987-01-01 00:00:00

abstract：:Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...

journal_title：International clinical psychopharmacology

authors： Liebowitz MR,Heimberg RG

更新日期：1996-06-01 00:00:00

abstract：:Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...

journal_title：International clinical psychopharmacology

authors： Montgomery SA

更新日期：2008-03-01 00:00:00

abstract：:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

journal_title：International clinical psychopharmacology

authors： Di Fiorino M,Montagnani G,Trespi G,Kasper S

更新日期：2014-05-01 00:00:00

abstract：:This retrospective cohort study was performed to investigate the association between risperidone and deteriorating performance in walking and dressing in subjects with Parkinson's disease using the Japanese Diagnosis Procedure Combination data. These data include inpatient claims including information from the time of...

journal_title：International clinical psychopharmacology

authors： Iketani R,Imai S,Horiguchi H,Furushima D,Fushimi K,Yamada H

更新日期：2019-09-01 00:00:00

abstract：:A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...

journal_title：International clinical psychopharmacology

authors： Lensch K,Fuchs G,Böning J,Milech U

更新日期：1987-04-01 00:00:00

abstract：:Social dysfunction is often associated with depressive disorders and its evaluation is an important measure of treatment outcome. The aim of this study was to assess the effect of two treatments, venlafaxine and amitriptyline, on the social functioning of depressed patients. Twenty-eight outpatients, meeting criteria ...

journal_title：International clinical psychopharmacology

authors： Gorenstein C,Andrade L,Moreno RA,Artes R

更新日期：2002-07-01 00:00:00

abstract：:Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...

journal_title：International clinical psychopharmacology

authors： Hawley CJ,Roberts AG,Baldwin DS

更新日期：1994-04-01 00:00:00

abstract：:Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

journal_title：International clinical psychopharmacology

authors： Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

更新日期：2008-11-01 00:00:00